Xencor (XNCR) Updates Its Pipeline, Is The Stock Still Cheap?
Xencor (XNCR) stock moved after updated phase I data for XmAb819 in renal cell carcinoma supported dose selection and planning for a pivotal study, along with progress in XmAb942 and upcoming first-in-human testing of XmAb412.
See our latest analysis for Xencor.
Xencor’s recent clinical updates have arrived alongside sharp share price momentum, with a 1 day share price return of 8.72% and a 30 day share price return of 61.79%. The 1 year total shareholder return of 122.28% contrasts with weaker 3 and 5 year total shareholder returns, suggesting enthusiasm around the current pipeline news is reshaping near term sentiment more than long run performance.
If you are looking beyond Xencor for other potential biotech ideas riding similar interest in advanced therapies, this could be a good time to review 39 healthcare AI stocks
After Xencor’s rapid rerating and a share price near $20.45, the decision now is simple but important: lean into the current momentum or wait for a pullback and risk missing any valuation gap that remains?
Most Popular Narrative: 28.2% Undervalued
With Xencor trading at $20.45 against a narrative fair value of $28.50, the current research framework points to a sizable valuation gap that hinges on pipeline execution.
The robust and flexible XmAb platform allows for modular drug development and the creation of differentiated assets, expected to reduce development costs and timelines, directly benefiting future operating margins and net profitability. Clinical trial strategy emphasizes efficient dose ranging and selection, ongoing biomarker efforts, and combination-therapy optionality, positioning the company to respond rapidly to evolving standards of care and maximize the commercial potential of its pipeline, with positive implications for recurring revenue and ultimate earnings leverage.
Curious what kind of revenue trajectory and margin shift would need to back up that higher value for Xencor? The most followed narrative leans on ambitious growth, a sharp profitability swing, and a premium earnings multiple that is far from typical for this sector.
Result: Fair Value of $28.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Xencor’s story could shift quickly if TL1A competitors win share in inflammatory bowel disease, or if key trials like XmAb942 face delays or weaker than expected data.
Find out about the key risks to this Xencor narrative.
Another View: How Xencor Screens On Sales-Based Valuation
The earlier fair value of $28.50 for Xencor rests on a forward looking narrative. Looking at today’s numbers, the current P/S of 15.6x is higher than the US Biotechs industry at 10.9x and far above a fair ratio of 0.8x, even though it is lower than peer levels at 38.8x. That mix of signals raises a simple question: is the valuation gap an opportunity or a margin of safety concern?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Xencor split between excitement over potential rewards and concern about key risks, it may be useful to act promptly and review the full picture yourself by weighing the 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Xencor?
Do not stop with Xencor alone. Broaden your watchlist with other stocks that fit clear themes and let the data surface ideas you might otherwise miss.
- Target high potential opportunities early by reviewing the 21 elite penny stocks with strong financials that stand out for their financial strength.
- Prioritize value by focusing on companies highlighted in the 50 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
- Put resilience first by scanning the 81 resilient stocks with low risk scores built around businesses with more robust risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com